Stocks and Investing Stocks and Investing
Thu, June 16, 2022
Wed, June 15, 2022
Tue, June 14, 2022
Mon, June 13, 2022
Sun, June 12, 2022
Fri, June 10, 2022

David Lebowitz Downgraded (BPMC) to Strong Sell and Decreased Target to $41 on, Jun 10th, 2022


Published on 2024-10-27 21:28:38 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Downgraded "Blueprint Medicines Corporation" (BPMC) to Strong Sell and Decreased Target from $68 to $41 on, Jun 10th, 2022.

David has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022
  • Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022


These are the ratings of the 3 analyists that currently disagree with David


  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022